Assembly Biosciences (ASMB) 10-K2022 FY Annual report

Filed: 22 Mar 23, 4:16pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Africa, aggressive, agonist, appointed, bioavailable, Bjorkquist, bridge, cancer, capsid, cHBV, CI, CIs, closure, CMC, Cmin, CMV, cofactor, compelling, conflict, curve, custodian, decentralize, delta, deposit, devastating, East, ECG, empty, enrollee, exacerbate, experimental, expressly, FDIC, FDORA, genital, Gunderson, HDV, helicase, HSV, ID, IFN, IFNAR, immune, immunosuppression, importantly, IRA, Jeanette, kinase, latent, lifelong, Middle, mild, MOA, modularity, modulatory, neonatal, NNPI, nonpublic, nucleoside, passage, paused, phosphorylation, plasma, poor, PPACA, primase, psychiatric, psychological, quantifiable, reactivate, reactivation, receptor, recession, recurrence, refocused, replenishment, retirement, revealed, satellite, shorter, signaling, Silicon, simplex, spectrum, subset, SVB, symptomatic, tablet, TCJA, thymidine, timeline, TK, uncontrolled, underway, uptake, Valley, varicella, VZV, weekly, workforce, zoster

Removed: AbbVie, accompany, acquiring, adefovir, aid, alafenamide, alfa, Allergan, approximated, ASC, attained, BBA, Bipartisan, body, budget, build, circulating, classify, clear, close, CMO, codification, community, computing, concluding, confidence, consistency, conventional, conversion, deduction, deeper, delivered, detectable, differentiated, digit, directed, disoproxil, donut, employer, enabling, entecavir, epidemic, Epivir, estate, excessive, execution, exist, faster, fight, finally, fixed, force, forge, foundation, freestanding, fumarate, gastrointestinal, generic, greatest, hardware, HBc, headcount, Hepsera, HHS, holder, hole, Holubiak, hour, imply, importance, inflammation, injection, Instance, interfere, intestine, invested, investigative, investor, involvement, issuable, JDC, lamivudine, landscape, lesser, listing, live, LLOQ, medically, microbial, minimize, modified, modify, modulating, monotherapy, Myron, NaN, negotiated, nondeductible, ordinarily, outbreak, outlined, partner, peer, ph, platform, pregnant, presidential, profit, promising, proportionately, rarely, recapitalization, recording, relaxed, restrictive, retrospective, salary, Schema, sensitivity, separation, social, split, stopped, supplemented, suppressive, suspending, synthetic, telbivudine, tenofovir, Therabiome, tightening, transcription, Tyzeka, undergo, underwriting, unexercised, updated, validation, Vemlidy, version, Viread, weigh, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ASMB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statements (Form S-3 No. 333-248469) of Assembly Biosciences, Inc.,

(2)

Registration Statement (Form S-8 No. 333-173613) pertaining to the Ventrus Biosciences, Inc. 2007 Stock Incentive Plan and the Ventrus Biosciences, Inc. 2010 Equity Incentive Plan,

(3)

Registration Statement (Form S-8 No. 333-182167) pertaining to the Ventrus Biosciences, Inc. 2010 Equity Incentive Plan,

(4)

Registration Statement (Form S-8 No. 333-198803) pertaining to the Assembly Biosciences, Inc. 2014 Stock Incentive Plan,

(5)

Registration Statement (Form S-8 No. 333-213019) pertaining to the Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan,

(6)

Registration Statement (Form S-8 No. 333-216902) pertaining to certain Non-Qualified Stock Option Agreements dated May 16, 2014,

(7)

Registration Statement (Form S-8 No. 333-219919) pertaining to the Assembly Biosciences, Inc. 2017 Inducement Award Plan,

(8)

Registration Statement (Form S-8 No. 333-226703) pertaining to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan and the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan,

(9)

Registration Statement (Form S-8 No. 333-233030) pertaining to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan,

(10)

Registration Statement (Form S-8 No. 333-234580) pertaining to the Assembly Biosciences, Inc. 2019 Inducement Award Plan and the Assembly Biosciences, Inc. Amended and Restated 2014 Stock Incentive Plan,

(11)

Registration Statement (Form S-8 No. 333-248476) pertaining to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan and the Assembly Biosciences, Inc. 2020 Inducement Award Plan,

(12)

Registration Statement (Form S-8 No. 333-258516) pertaining to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan and the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan,

(13)

Registration Statement (Form S-8 No. 333-266711) pertaining to the Assembly Biosciences, Inc. 2018 Stock Incentive Plan,

of our report dated March 22, 2023, with respect to the consolidated financial statements of Assembly Biosciences, Inc. included in this Annual Report (Form 10-K) of Assembly Biosciences, Inc. for the year ended December 31, 2022.

/s/ Ernst & Young LLP

San Jose, California

March 22, 2023